Product Description
Rezafungin is being developed by Cidara for the treatment of patients with Invasive Fungal Infections. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04368559?term=Rezafungin&draw=2&rank=4)
Mechanisms of Action: Glucan Synthase Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Cidara
Company Location: SAN DIEGO CA 92121
Company CEO: Jeffrey Stein
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, France, Germany, Italy, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Candidemia|Candidiasis, Invasive|Communicable Diseases|Fungemia|Invasive Fungal Infections|Liver Transplant|Pneumocystis Infections|Pneumonia, Pneumocystis|Stem Cell Transplant
Phase 2: Pulmonary Aspergillosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STUDY24080165 | P3 |
Not yet recruiting |
Communicable Diseases|Liver Transplant |
2028-12-01 |
|
| MR907-2502 | P2 |
Not yet recruiting |
Pulmonary Aspergillosis |
2026-02-28 |
|
| ReSPECT | P3 |
Recruiting |
Candidiasis, Invasive|Communicable Diseases|Invasive Fungal Infections|Candidemia|Fungemia|Pneumocystis Infections|Pneumonia, Pneumocystis |
2025-12-01 |
|
| MR907-2501 | P2 |
Recruiting |
Pneumonia, Pneumocystis |
2025-05-01 |